Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the tolerability and effectiveness of four FDA-approved treatments
in Neurofibromatosis Type 1 Cutaneous Neurofibromas. These treatments are: a 980nm laser, a
755nm laser, radio-frequency injection, and a Kybella injection. Each patient will have a
treatment and a control site.